SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.950
-0.080 (-3.94%)
At close: Jun 27, 2025, 4:00 PM
1.970
+0.020 (1.00%)
After-hours: Jun 27, 2025, 7:59 PM EDT
SLS Employees
SELLAS Life Sciences Group had 15 employees as of December 31, 2024. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,808,533
Market Cap
194.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SLS News
- 23 days ago - SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts - GlobeNewsWire
- 26 days ago - SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - GlobeNewsWire
- 2 months ago - SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewsWire